Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells

Blood

Volumn 104, Issue 10, 2004, Pages 3126-3135

  Tenedini, Elena ^b   Fagioli, Maria Elena ^b   Vianelli, Nicola ^b   Tazzari, Pier Luigi ^b   Ricci, Francesca ^b   Tagliafico, Enrico ^b   Ricci, Paolo ^b   Gugliotta, Luigi ^b   Martinelli, Giovanni ^b   Tura, Sante ^b   Baccarani, Michele ^b   Ferrari, Sergio ^b   Catani, Lucia ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DNA; LIPOCORTIN 5; PROTEIN; PROTEIN BAX; PROTEIN BNIP3; PROTEIN BNIP3L; PROTEIN CFLAR; PROTEIN IGF1 R; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOCYTHEMIA; UNINDEXED SEQUENCE;

EID: 8644250701     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2597     Document Type: Article

References (63)

1. Crippe LD, Hromas R. Malignant disorders of megakaryocytes. Sem Hematol. 1998;35:200-209.
2. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev. 2001;15:159-166.
3. Schafer AI. Thrombocytosis: too much of a good thing? Trans Am Clin Climatol Assoc. 2002;113:68-76.
4. Catani L, Gugliotta L, Cascione ML, et al. Platelet function and interferon alpha-2atreatment in essential thrombocythaemia. Eur J Haematol. 1991;46:158-162.
5. Green AR. The pathogenesis and management of essential thrombocythemia. Haematologica. 1999;84:36-39.
6. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica. 2000;85:1126-1134.
7. Harrison CN, Gale RE, Machin SI, Lynch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417-424.
8. Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S, Green AR. Clonal hematopoiesis in normal elderly woman: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol. 1997;97:920-926.
9. Zauli G, Catani L. Human megakaryocyte biology and pathophysiology. Crit Rev Oncol Hematol. 1995;21:135-137.
10. Baatout S. Megakaryocytopoiesis: growth factors, cell cycle and gene expression. Anticancer Res. 1998;18:1871-1882.
11. Norol F, Vitrat N, Cramer E, et al. Effects of cytokines on platelet production from blood and marrow CD34+ cells. Blood. 1998;91:830-843.
12. Italiano JE, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 147:1299-1312.
13. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397-407.
14. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002;108:55-65.
15. Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillières Clin Haematol. 1998;11:819-848.
16. Zamora L, Espinet B, Florensa L, Besses C, Salido M, Solè F. Incidence of trisomy 8 and 9, deletion of D13S319 and D20S108 loci and BCR/ABL translocation in non-treated essential thrombocythemia patients: an analysis of bone marrow cells using interphase fluorescence in situ hybridization [letter]. Haematologica. 2003;88:110-111.
17. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Polycythemia Vera Study Group. Semin Thromb Haemost. 1997;23:339-347.
18. Catani L, Vianelli N, Amabile M, et al. NF-E2 expression in normal and malignant megakaryocytopoiesis. Leukemia. 2002;16:1773-1781.
19. Zauli G, Catani L, Gibellini D, et al. The CD4 receptor plays essential but distinct roles in HIV-1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa+ megakaryocytes and the HEL cell line. Br J Haematol. 1995;91:290-298.
20. MacDonald RJ, Swift GH, Przybyla AE, Chirgwin JM. Isolation of RNA using guanidinium salts. Methods Enzymol. 1987;152:219-227.
21. Tagliafico E, Tenedini E, Bergamaschi A, et al. Gene expression profile of Vitamin D3 treated KHL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Cell Death Differen. 2002;9:1185-1195.
22. Liu WM, Mei R, Di X, et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics. 2002;18:1593-1599.
23. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology: The Gene Ontology Consortium. Nat Genet. 2000;25:25-29.
24. Philips DR, Charo IF, Parise LV, et al. The platelet membrane glycoprotein Iib-IIIa complex. Blood. 1988;71:831-843.
25. Lopez J. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis. 1994;5:97-119.
26. IIb-β3 integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34+ cord blood cells to megakaryocytes. Blood. 2000;96:4169-4177.
27. Clay D, Rubinstein E, Mishal Z, et al. CD9 and megakaryocyte differentiation. Blood. 2001;97:1282-1289.
28. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101:2285-2293.
29. Di Noto R, Luciano L, Lo Pardo C, et al. Jurf-MK1 and JURL-MK2 cell lines: two sided model for investigating leukemic magakaryocytopoiesis. Leukemia. 1997;11:1554-1564.
30. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-1326.
31. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3:298-302.
32. Bellucci S, Michiels JJ. Spontaneous proliferative megakaryocytopoiesis and platelet hyperreactivity in essential thrombocythemia: is thrombopoietin the link? Ann Hematol. 2000;79:51-58.
33. Taksin AL, Le Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by mpl-L. Blood. 1999;93:125-139.
34. Axelrad AA, Eskinazi D, Correa PN, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310-3321.
35. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350:1211-1219.
36. Tefferi A. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia agnogenic myeloid metaplasia and chronic myelogenous leukemia. Semin Hematol. 1999;36:3-8.
37. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia. Nat Genet. 1998;18:49-53.
38. Harrison CN, Gale RE, Wiesner AC, Skoda RC, Linch DC. The activating splice donor mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythemia. Br J Haematol. 1998;102:1341-1343.
39. Kiladjan JJ, El Kassar N, Hetet G, Briere J, Grandchamp B, Gardin C. Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia. 1997;11:1821-1826.
40. Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90:2234-2243.
41. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100:1310-1317.
42. Clarke MCH, Savill J, Jones DB, et al. Compartimentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol. 2003;17:577-587.
43. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
44. Gupta S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sciences. 2001;69:2957-2964.
45. Wei Mc, Zong WX, Cheng EH-Y, et al. Proapototic BAX or BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727-730.
46. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-Flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J Biol Chem. 1997;272:17255-17257.
47. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci. 2003;60:267-276.
48. Werner H, Karnieli E, Rauscher FJ, LeRoth D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A. 1996;93:8318-8323.
49. Hodohara K, Fujii N, Yamamoto N, Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood. 2000;95:769-775.
50. Guerriero R, Mattia G, Testa U, et al. Stromal cell-derived factor 1 alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood. 2001;97:2587-2595.
51. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125-139.
52. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. New Engl J Med. 1998;338:564-571.
53. Giraudier S, Chagraoui H, Komura E, et al. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood. 2002;100:2932-2940.
54. Italiano JE Jr, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost. 2003;1:1174-1182.
55. Mouthon MA, Navarro S, Katz A, Breton-gorius J, Vainchenker W. c-Jun and c-fos are expressed by human megakaryocytes. Exp Hematol. 1992;20:909-915.
56. Panterne B, Hatzfeld J, Blanchard JM, et al. c-fos mRNA constitutive expression by mature human megakaryocytes. Oncogene. 1992;7:2341-2344.
57. Garcia M, Samarut J. v-jun cooperates with verbB to transform the thrombocytic/megakaryocytic lineage. Proc Natl Acad Sci U S A. 1993;90:8837-8841.
58. Elagib KE, Racke FK, Mogass M, Khetawat R, Deleha LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341.
59. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: review. Pediat Hemat Oncol. 1992;9:139-149.
60. Michaud J, Wu F, Osato M, et al. In vitro analysis of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 99:1364-1372.
61. Takeuchi K, Higuchi T, Yamashita T, Koike K. Chemokine production by human megakaryocytes derived from CD34-positive cord blood cells. Cytokine. 1999;11:424-434.
62. Daly TJ, LaRosa GJ, Dolich S, et al. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet 4. J Biol Chem. 1995;270:23282-23292.
63. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12:375-391.